Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies

Summary

This phase I trial studies the side effects and best dose of Hsp90 inhibitor AUY922 in treating older patients with advanced solid malignancies. Hsp90 inhibitor AUY922 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Timeline

Start

2011-09

Primary completion

2012-02

Completion

2012-02

Drugs

Indications